Table 1.
N = 21 | No | % |
---|---|---|
Gender | ||
Male | 7 | 46.7 |
Female | 8 | 53.3 |
Age (years) | ||
Median | 54.2 | |
Range | 29–81 | |
Histology | ||
Adenocarcinoma | 14 | 93.3 |
Squamous cell carcinoma | 1 | 6.7 |
ECOG PS | ||
0 | 2 | 13.3 |
1 | 10 | 66.7 |
2 | 3 | 20.0 |
Smoking history | ||
Never | 11 | 73.3 |
Former | 4 | 16.7 |
EGFR mutation type | ||
19 del | 9 | 60.0 |
21 L858R | 5 | 33.3 |
18 G719X | 1 | 6.7 |
Best response to TKI | ||
CR | 2 | 13.3 |
PR | 8 | 53.4 |
SD | 5 | 33.3 |
Line of EGFR‐TKI | ||
First‐line | 9 | 60 |
Second/third‐line | 6 | 40 |
Site of RECIST PD | ||
Lung | 10 | 66.7 |
Liver | 4 | 16.6 |
Adrenal | 1 | 6.7 |
CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non‐small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.